Phase IIa study of tosposertib, a dual TGFβRI and VEGFR2 inhibitor, in combination with pembrolizumab in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Yonsei University, Yonsei Cancer Hospital, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Yonsei University Health System, Seoul National University, Seoul National University Bundang Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, The Catholic University of Korea St. Vincent's Hospital, Konkuk University, Konkuk University Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162485339
Cites:
Cited by:
Related to: